Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 5/20 | 0.37 |
| ▸ | RXRB | P28702 | 4/20 | 0.37 |
| ▸ | RXRG | P48443 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493534 | 0.82 | ACLY (0.36) | ALDH1A1L3MBTL1KDM4ETDP1ACLY | |
| SCHEMBL493566 | 0.78 | BDKRB1 (0.42) | ALDH1A1L3MBTL1KDM4ETDP1BDKRB1 | |
| SCHEMBL642948 | 0.78 | GAA (0.48) | ALDH1A1L3MBTL1KDM4EFABP4GAA | |
| SCHEMBL644589 | 0.77 | GAA (0.47) | ALDH1A1L3MBTL1KDM4EFABP4GAA | |
| SCHEMBL5130046 | 0.72 | KDM4E (0.46) | KDM4ETDP1BDKRB1 | |
| SCHEMBL493606 | 0.71 | ACLY (0.38) | ALDH1A1L3MBTL1KDM4EACLY | |
| SCHEMBL4475597 | 0.70 | KDM4E (0.41) | KDM4ETDP1BDKRB1HPGD | |
| SCHEMBL645268 | 0.69 | MAPT (0.45) | L3MBTL1KDM4EACLY | |
| SCHEMBL4484352 | 0.68 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL4032633 | 0.67 | HTT (0.48) | ALDH1A1L3MBTL1KDM4EBDKRB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | ALDH1A1 1349/4885L3MBTL1 4753/4885RXRA 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.